Nanjing Tridie Pharmaceutical Technology

About Nanjing Tridie Pharmaceutical Technology

Nanjing-based Triastek, established in July 2015 by CEO Dr. Senping Cheng and Professor Xiaoling Li, operates at the forefront of pharmaceutical manufacturing through 3D printing technology. The company originated from Professor Li's scientific hypothesis of using 3D printing to transform drug development and production. Triastek has secured significant financial backing, raising a total of $102 million over four funding rounds, including a $20.4 million Series B round in September 2023. Investors include notable firms such as Matrix Partners China, Morningside, and Shanghai Guoxin Investment Development.

Triastek's core business revolves around its proprietary Melt Extrusion Deposition (MED) technology, a form of additive manufacturing that converts powdered raw materials into precisely layered solid oral dosage forms. This digital process allows for the creation of complex geometric structures within a tablet, enabling programmed and controlled drug release. The company's business model includes developing its own pipeline of drugs and co-developing products with global pharmaceutical partners like Eli Lilly, Merck KGaA, Boehringer Ingelheim, and BioNTech. These collaborations focus on solving complex formulation challenges, accelerating drug development, and improving medication quality. Revenue is generated through these partnerships, which may involve upfront payments, milestone payments, and licensing agreements.

The company's primary offering is its end-to-end 3D printing pharmaceutical platform, which covers dosage form design, digital product development, and intelligent manufacturing. A key feature is the 3DFbD® (Formulation by Design) approach, which allows for rapid prototyping and simulation of drug release profiles, significantly shortening development cycles. Triastek has developed several technology platforms, including 3D Microstructure for Modified Release (3DμS®-MR) and Gastric Retention (3DμS®-GR), to address diverse clinical needs. This has led to multiple products receiving Investigational New Drug (IND) clearance from the U.S. FDA, including T19 for rheumatoid arthritis, T20, T21, and T22 for pulmonary hypertension. The company's MED technology was accepted into the FDA's Emerging Technology Program in 2020, and it has built a GMP-compliant continuous production line capable of producing up to 75 million units annually.